OTC Docket(s): 20140357 Term Sheet Version: v1.0 **Document Revision Date:** 09/08/2020

University of Minnesota

NON-BINDING BUSINESS TERM SHEET TRY AND BUY LICENSE FOR DISCUSSION PURPOSES ONLY

Title: 20140357 Try & Buy

Company:
Marketing Manager: Kenny Karanja

MIAIK	wanketing wanager. Kenny Karanja					
		COMPANY INFOR	RMATION			
			Attn:			
		Name and Address	Entity Type: Registered In: Phone: Email:			
		TECHNOLO	GY			
	Title:	20140357 - MCC22, A Highly Effect Chemoki	tive Bivalent Ligand that Targets Opioid-			
		TRY Term	as .			
	1.	Effective Date				
	2.	TRY Period	Up to 24 Months			
	3.	TRY Fee	Second 12 Months, \$5,000 Paid at time of Effective Date of the TRY Period Fee waived if MN-based company or if sponsoring \$50,000+ research with the University			
	4.	Equity	Start-up companies must work with the University on equity terms			
	5.	Patent Related Expenses (During TRY Term)	US Patent Expenses: Company is not responsible for reimbursing the University for US Patent Related Expenses during the TRY Period.			
			Foreign Patent Expenses: Company is not responsible for reimbursing the University for Foreign Patent Related Expenses during the TRY Period.			
		BUY Term				
(if converted from TRY to BUY)						
	Α.	License Type	Exclusivity: Exclusive License Type: Try & Buy - Patent Distribution Type: Distribution			

B.	Field(s) of Use	All
C.	Territory	All territories where the University has
		licensable IP.
D.	Term	Life of the University's licensable IP (patents
		or copyrights).
E.	Sublicense Rights	Yes
F.	Federal Government Rights	Yes
G.	Milestones	- \$50,000 payment for submission of NDA to
		FDA, or foreign equivalent, by 60 months
		from the Effective Date.
		- Initiation of clinical trials within 24 months
		from the Effective Date of the Buy period.
Н.	Commercialization Reports	Annually
I.	1	Payments
	Conversion Payment	\$ 25,000, due at time of conversion from TRY
	Conversion 1 ayment	to BUY license. Conversion request must be
		received by the University prior to the
		expiration of the TRY period.
	Annual Administration Fee	- \$5000 annual minimum credited against
		royalties thereafter.
	Running Royalty / Royalty	- 3% of net sales of licensed products. This is
	Holiday / Minimums	reduced to 2% for a MN-based company. Paid
	11011day / 1/11111111dailis	Quarterly. No Running Royalty is due until \$1
		million of Cumulative Net Commercial Sales
		of Licensed Product have been reached.
		- \$0 credited to annual royalties, until
		\$1,000,000 of Cumulative Net Commercial
		Sales of Licensed Products have been reached.
	Sublicense Fees	- Paid Quarterly.
		- 3% of all Sublicensee's net sales of licensed
		products.
		- 50% of all Sublicense Revenues.*
		*These are payments made by the Sublicensee(s) tha
		are not royalties based on Net Sales. For example, Sublicense Revenues would include Upfront Fees
		paid by the Sublicensee.
	Equity	Start-up companies must work with the
		University on equity terms
	Change of Control / Assignment /	Greater of \$25000 or 0.5% of Gross
	Transfer	Distributable Proceeds upon Qualified Sale.
	Interest Rate	12%
	Other	
J.	Patent Related Expenses (During	US Patent Expenses: As of the Effective Date
	BUY Term)	of the agreement, Licensee is responsible for
		paying all Patent Related Expenses once paten
		issues.
		Contact Technology Commercialization for
		the current US and Foreign patent expenses.
m Sheet	The terms set forth in this Term Shee	et are valid for discussion purposes for 30 days
iration	from the initial contact with the Univ	rersity.

READ CAREFULLY

This term sheet summarizes the principal terms with respect to a possible license of University technology to the entity listed in section 1 as Potential Licensee. This term sheet is intended solely as a basis for further discussion and is not intended to be and does not constitute a legally binding obligation. No other legally binding obligations will be created, implied, or inferred until a license agreement (e.g., 'Exclusive Patent License Agreement', 'Non-Exclusive Patent License Agreement', 'Plant License Agreement', 'Software License Agreement', etc.) in final form is executed and delivered by all the parties. Without limiting the generality of the foregoing, it is the parties intent that, until that event, no agreement shall exist among them and there shall be no obligations whatsoever based on such things as parol evidence, extended negotiations, "handshakes," exchanges of emails, oral understandings, or courses of conduct (including reliance and changes of position), except as may be outlined in a non-disclosure agreement with respect to the confidentiality obligations of the parties regarding any exchange of confidential information. Nothing in this term sheet is to be construed to prevent the University from discussing similar terms with other potential licensees.